ChemDiv has been a pioneer in discoverylibraries since 1991. Its first diverse heterocyclic compounds collection wascompiled from academic lab sources from all over the world, and ChemDivsubsequently successfully launched its own large-scale library synthesis program.
ChemDivis now the recognized global leader in discovery chemistry with the industry'slargest, most diverse, and most pharmacologically-relevant commercialcollection of over 1,500,000 individually crafted, lead-like, drug-like smallmolecules. ChemDiv executes pre-clinical chemistry and biology for drugdevelopment and clinical trials for an international portfolio of companiesacross the entire range of targets with small molecule and biotech drugs. Thecompany operates multiple research and development (R&D) subsidiaries inRussia, Ukraine and China as well as business operations around the world. Ourlaboratories are equipped for both 'GLP-like' and GLP research standards tomeet our international research and business partners' needs.
Wecustom-tailor our professional assistance to best meet your R&D Chemistry,Biology and Clinical needs. We pride ourselves on being one of the industry'smost experienced CROs, with hands-on expertise in every aspect of both earlyand clinical development of anti-infectives and antivirals, oncologics, CNS,cardiometabolics, and anti-inflammatory therapies. Our track record spanssuccessful and timely delivery of discovery libraries, target-biased compoundsets reflective of modern trends in Chemical Biology, pathway analysis, invitro/ex vivo and in vivo assay development and implementation, as well as amultitude of modern drug discovery and evaluation platforms all aimed ataccelerated cost-effective R&D. Our integrated Discovery outSourceTMsolutions cover all disciplines needed to bring a project from target ID toPhase III clinical candidate and beyond.
Representativeexamples of our services include synthetic chemistry, structural biology andstructure-based drug discovery, molecular modeling, medicinal chemistry,scale-up, biochemical and cellular assay development, analytical/bioanalyticalplatforms, ADME/tox, DMPK and multiple in vivo efficacy/tox models.
Ourcollaborators range from large, midsize, and small Pharma/Biotech, to academia,foundations and screening centers. Every request and project gets attention ofour expert team.
Wecan offer a number of flexible business models that help you to manage yourdevelopment risk, conserve your R&D budget, and appropriately rewardsuccessful development outcomes.
Torequest more about our products and services or partnering opportunitiescontact us.
